| Nov 15 |
NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript
|
| Nov 15 |
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage
|
| Nov 12 |
NeurAxis reports Q3 results
|
| Nov 12 |
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 5 |
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
|
| Nov 4 |
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
|
| Oct 29 |
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024
|
| Oct 22 |
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
|
| Sep 25 |
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation
|
